Song Bohan, Bai Jinfeng, Zhou Jinmei, Yang Yinshan, Wu Qijie, Huang Ming, Fan Hongjie, Cheng Xianshuo, Liu Ping, Xiao Yu-Dong, Zhao Xin, Deng Chongying, Luo Shuai, Ding Rong
Department of Minimally invasive intervention, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2025 May 29;15:1522470. doi: 10.3389/fonc.2025.1522470. eCollection 2025.
This study aims to retrospectively analyze the safety and effectiveness of microwave ablation (MWA) in treating multiple lung metastases from colorectal cancer. Additionally, it seeks to compare the superiority of single multiple ablation and fractionated multiple ablation for unilateral lung multiple metastases.
Retrospective analysis was conducted on clinical and pathological data of 82 patients with such multiple lung metastases from colorectal cancer treated from January 2020 to December 2022. Patients were categorized based on the number of MWA sessions required,Patients who had received only one MWA treatment were included in the single MWA group, and patients who had received two or more MWA treatments were included in the multiple MWA group. Chest-enhanced CT scans were performed at 1, 3, 6, and 12 months post-MWA to assess ablation outcomes. The primary focus was the median overall survival (mOS), while secondary endpoints encompassed median progression-free survival (mPFS), technical success rates, and safety. Analysis was performed by log-rank test and Cox proportional hazard regression model, using the Common Terminology Standard for Adverse Events (version 5.0) to assess safety within 28 days after MWA.
There were 82 patients with numerous lung metastases from colorectal cancer, and they had a total of 182 lesions. These patients underwent 112 microwave ablation (MWA) treatments. Each patient received at least two MWA treatments for their target lesions. The overall median overall survival (mOS) time for all patients was 25 months, the median progression-free survival (mPFS) time was 21 months. No deaths or severe adverse events occurred as a result of the treatment. The univariate Cox regression analysis indicated that fractional MWA (=0.007) were adverse prognostic factors for CRC patients with lung metastasis.Upon accounting for various confounding factors, the significance of MWA times (=0.006) remained pertinent in its association. Furthermore, the group that underwent single MWA showed a superior mOS compared to the group that underwent fractionated MWA (=0.004).
Microwave ablation proves to be a safe and efficacious treatment modality for colorectal cancer-associated multiple pulmonary metastases, offering substantial clinical benefits.
本研究旨在回顾性分析微波消融(MWA)治疗结直肠癌多发肺转移的安全性和有效性。此外,旨在比较单次多次消融和分次多次消融治疗单侧肺多发转移的优势。
对2020年1月至2022年12月期间接受治疗的82例结直肠癌多发肺转移患者的临床和病理资料进行回顾性分析。根据所需MWA疗程数对患者进行分类,仅接受一次MWA治疗的患者纳入单次MWA组,接受两次或更多次MWA治疗的患者纳入多次MWA组。在MWA后1、3、6和12个月进行胸部增强CT扫描,以评估消融效果。主要重点是中位总生存期(mOS),次要终点包括中位无进展生存期(mPFS)、技术成功率和安全性。采用对数秩检验和Cox比例风险回归模型进行分析,使用不良事件通用术语标准(第5.0版)评估MWA后28天内的安全性。
82例结直肠癌多发肺转移患者共有182个病灶。这些患者接受了112次微波消融(MWA)治疗。每位患者针对其靶病灶至少接受了两次MWA治疗。所有患者的总体中位总生存期(mOS)时间为25个月,中位无进展生存期(mPFS)时间为21个月。治疗未导致死亡或严重不良事件。单因素Cox回归分析表明,分次MWA(=0.007)是结直肠癌肺转移患者的不良预后因素。在考虑各种混杂因素后,MWA次数(=0.006)的意义在其关联中仍然相关。此外,单次MWA组的mOS优于分次MWA组(=0.004)。
微波消融被证明是治疗结直肠癌相关多发肺转移的一种安全有效的治疗方式,具有显著的临床益处。